Bristol-Myers Squibb Company
Bristol-Myers Squibb Company
430 E. 29th Street, 14th Floor,
New York, NY 10016
Phone: 1-800-332-2056Website: https://www.bms.com/Careers: www.bms.com/careers/Pages/home.aspxPatient Assistance Program: www.bms.com/products/Pages/programs.aspx
Latest news
- U.S. FDA Approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
28 August 2023 - Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
16 August 2023 - U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
30 May 2023 - OncoSec presents encouraging early data with TAVO-EP combined with Opdivo in neoadjuvant melanoma
15 November 2022 - Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
10 September 2022 - FDA Approves Sotyktu (deucravacitinib) for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
9 September 2022 - Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
27 July 2022 - U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
24 June 2022 - Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus
1 June 2022 - U.S. Food and Drug Administration Approves Two Opdivo (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
30 May 2022
Drugs Associated with Bristol-Myers Squibb Company
Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 36 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Brand/Generic Name | Reviews | Rating |
---|---|---|
Abecma
Generic name: idecabtagene vicleucel Drug class: miscellaneous antineoplastics |
||
Abraxane
Generic name: paclitaxel protein-bound Drug class: mitotic inhibitors |
5 reviews | 6.2 / 10 |
Atripla
Generic name: efavirenz/emtricitabine/tenofovir Drug class: antiviral combinations |
99 reviews | 9.1 / 10 |
Azactam
Generic name: aztreonam Drug class: miscellaneous antibiotics |
||
Baraclude
Generic name: entecavir Drug class: nucleoside reverse transcriptase inhibitors (NRTIs) |
1 review | 10 / 10 |
Breyanzi
Generic name: lisocabtagene maraleucel Drug class: miscellaneous antineoplastics |
||
Camzyos
Generic name: mavacamten Drug class: miscellaneous cardiovascular agents |
||
Coumadin
Generic name: warfarin Drug class: coumarins and indandiones |
21 reviews | 8.9 / 10 |
Droxia
Generic name: hydroxyurea Drug class: antimetabolites |
||
Eliquis
Generic name: apixaban Drug class: factor Xa inhibitors |
191 reviews | 4.9 / 10 |
Empliciti
Generic name: elotuzumab Drug class: miscellaneous antineoplastics |
||
Etopophos
Generic name: etoposide Drug class: mitotic inhibitors |
||
Evotaz
Generic name: atazanavir/cobicistat Drug class: antiviral combinations |
||
Hydrea
Generic name: hydroxyurea Drug class: antimetabolites |
8 reviews | 7.2 / 10 |
Idhifa
Generic name: enasidenib Drug class: miscellaneous antineoplastics |
||
Inrebic
Generic name: fedratinib Drug class: multikinase inhibitors |
||
Istodax
Generic name: romidepsin Drug class: histone deacetylase inhibitors |
1 review | 1.0 / 10 |
Kenalog
Generic name: triamcinolone Drug class: topical steroids |
29 reviews | 8.3 / 10 |
Lysodren
Generic name: mitotane Drug class: miscellaneous antineoplastics |
||
Nulojix
Generic name: belatacept Drug class: selective immunosuppressants |
1 review | 10 / 10 |
Onureg
Generic name: azacitidine Drug class: miscellaneous antineoplastics |
||
Opdivo
Generic name: nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
68 reviews | 4.8 / 10 |
Opdualag
Generic name: nivolumab/relatlimab Drug class: antineoplastic combinations |
||
Orencia
Generic name: abatacept Drug class: antirheumatics, selective immunosuppressants |
64 reviews | 5.9 / 10 |
Plavix
Generic name: clopidogrel Drug class: platelet aggregation inhibitors |
52 reviews | 7.3 / 10 |
Pomalyst
Generic name: pomalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants |
3 reviews | 10 / 10 |
Reblozyl
Generic name: luspatercept Drug class: miscellaneous erythropoiesis agents |
2 reviews | 10 / 10 |
Revlimid
Generic name: lenalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants |
18 reviews | 6.9 / 10 |
Reyataz
Generic name: atazanavir Drug class: protease inhibitors |
3 reviews | 8.3 / 10 |
Sotyktu
Generic name: deucravacitinib Drug class: multikinase inhibitors |
5 reviews | 3.6 / 10 |
Sprycel
Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors |
21 reviews | 7.5 / 10 |
Sustiva
Generic name: efavirenz Drug class: NNRTIs |
6 reviews | 5.2 / 10 |
Thalomid
Generic name: thalidomide Drug class: leprostatics, miscellaneous antineoplastics, other immunosuppressants |
||
Vidaza
Generic name: azacitidine Drug class: miscellaneous antineoplastics |
14 reviews | 5.9 / 10 |
Yervoy
Generic name: ipilimumab Drug class: anti-CTLA-4 monoclonal antibodies |
2 reviews | 9.5 / 10 |
Zeposia
Generic name: ozanimod Drug class: selective immunosuppressants |
4 reviews | 7.5 / 10 |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |
Discontinued Drugs
Brand/Generic Name | Reviews | Rating |
---|---|---|
Glucophage
Generic name: metformin Drug class: non-sulfonylureas |
38 reviews | 6.9 / 10 |
Glucophage XR
Generic name: metformin Drug class: non-sulfonylureas |
10 reviews | 7.8 / 10 |
Pravachol
Generic name: pravastatin Drug class: statins |
11 reviews | 6.4 / 10 |
Videx
Generic name: didanosine Drug class: nucleoside reverse transcriptase inhibitors (NRTIs) |
||
Videx EC
Generic name: didanosine Drug class: nucleoside reverse transcriptase inhibitors (NRTIs) |
||
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |